NCT ID | NCT01988896 |
Title | A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase I |
Variant Requirements | yes |
Sponsors | Hoffmann-La Roche |
Indications | |
Therapies | |
Age Groups: | adult senior |